NASDAQ$MIRM
Mirum Pharmaceuticals Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Mirum reported Q1 2026 product sales of $159.9M and a net loss of $790.2M after a $726.3M acquired IPR&D charge, with diluted loss per share of $13.43.
Product sales, net rose to $159.9 million from $111.6 million (+43% YoY). The quarter included a $726.3 million acquired in-process R&D charge related to a business combination, driving a net loss of $790.2 million, or $13.43 per diluted share. Excluding that charge, operating trends reflect growing Livmarli/Chenodal volumes and higher R&D for pipeline assets.
- Product sales $159.9M (+43% YoY).
- Net loss $(790.2)M includes $726.3M IPR&D.
- Diluted loss per share $(13.43).
- R&D $97.9M as pipeline investments continue.
Headline financials
Revenue & EPS history
Mirum Pharmaceuticals · Revenue · Quarterly
$160M
Revenue by segment
Mirum Pharmaceuticals · $29.1M total across 1 segment · Q1 2023
- Net Product Sales$29.1M—100.0%
Forward guidance
The 10-Q focuses on integration and launch execution rather than issuing numeric consolidated EPS guidance.
Tailwinds
- Commercial rare-disease portfolio scaling double digits.
- Strategic transaction expands long-term pipeline optionality.
- Interest income partially offsets cash burn.
Headwinds
- Large one-time IPR&D charge distorts GAAP earnings.
- Integration and clinical/regulatory execution risk.
- High ongoing R&D and SG&A for growth assets.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+1.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+2.9%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+26.4%
Q2 2022
Best reaction
-16.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.0% | +0.2% | -11.7% | |
| Q4 2025 | -15.1% | -19.2% | -18.6% | |
| Q3 2025 | -1.4% | -1.8% | -3.5% | |
| Q1 2025 | +9.9% | +9.8% | +12.5% | |
| Q4 2024 | -7.0% | -10.5% | -9.0% | |
| Q3 2024 | +5.6% | +6.9% | +1.6% | |
| Q2 2024 | +1.8% | +14.3% | +5.0% | |
| Q1 2024 | -0.3% | -4.4% | -3.2% | |
| Q4 2023 | -3.0% | -3.1% | -15.2% | |
| Q3 2023 | +5.6% | +5.6% | +12.6% | |
| Q2 2023 | +6.1% | +2.1% | +6.1% | |
| Q1 2023 | -8.3% | -7.9% | -7.9% | |
| Q4 2022 | -1.1% | -4.7% | +5.1% | |
| Q3 2022 | -16.2% | -19.7% | -24.1% | |
| Q2 2022 | +26.4% | +18.0% | +7.4% | |
| Q1 2022 | +7.1% | -4.4% | +7.0% | |
| Q4 2021 | +3.3% | +1.5% | +29.5% | |
| Q3 2021 | +0.1% | -1.2% | -7.9% | |
| Q2 2021 | +0.5% | -4.0% | +23.0% | |
| Q1 2021 | -1.4% | -6.3% | -10.8% | |
| Q4 2020 | +6.0% | +14.3% | +10.2% | |
| Q3 2020 | +11.6% | +16.9% | +48.0% | |
| Q2 2020 | +13.0% | +15.3% | -4.3% | |
| Q1 2020 | +0.1% | +6.2% | +10.8% | |
| Q4 2019 | +8.1% | -10.5% | +25.7% | |
| Q3 2019 | -0.1% | +4.0% | +22.6% | |
| Q2 2019 | -9.0% | -10.3% | -31.5% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro